IDStewardship

  • Home
  • Articles
  • LEARN ANTIBIOTICS
  • Study Guide
  • Resources
  • Q&A
  • #ASPchat
  • Contributors
  • About

Is Clindamycin Or Linezolid Better For Toxin Mediation In Necrotizing Infections?

 



Question

Is clindamycin or linezolid better for toxin mediation in necrotizing infections?


Answer

Clindamycin has traditionally been the go-to drug for toxin mediation in necrotizing soft tissue infections caused by Group A Streptococcus (GAS, Streptococcus pyogenes, flesh eating bacteria). It is routinely added onto empiric therapy (e.g., vancomycin + piperacillin-tazobactam) for this purpose. Recent data have emerged bringing linezolid into the picture as a second potential option for toxin mediation.

Clindamycin is one of the highest risk antibiotics for causing C. difficile infection (CDI). Using linezolid instead avoids this risk. Linezolid also has better gram-positive coverage as compared to clindamycin, meaning that it is possible to even nix the empiric vancomycin when adding on linezolid for toxins. Removing vancomycin from the picture may reduce the risk for acute kidney injury.

Critics of linezolid cite its many concerning potential toxicities (e.g., serotonin syndrome, thrombocytopenia, optic neuritis).

Nicolás Cortés-Penfield, MD and Jonathan Ryder, MD debated the question in this article, highlighting rapidly growing resistance of GAS to clindamycin and severe lack of clinical data suggesting clindamycin offers any benefit for necrotizing soft tissue infections in clindamycin-resistant GAS strains. It is unclear what the impact of clindamycin resistance has on its use as an anti-toxin agent.

A fortunate side-effect of unfortunate drug shortages is the added weight to consider alternative strategies. With an ongoing intermittent clindamycin shortage, data have become available suggesting that in patients with necrotizing soft tissue infections and timely surgical management, clindamycin and vancomycin is associated with worse outcomes compared to similar patients using linezolid instead. 

In summary, there are no data to firmly say linezolid or clindamycin is best for necrotizing soft tissue infection. The risks and benefits of each option must be considered in the context of each unique patient case when making a treatment plan for this indication. Either seem to be viable options.



READINGS / RESOURCES

  • Clindamycin plus Vancomycin versus Linezolid for Treatment of Necrotizing Soft Tissue Infection
  • Should Linezolid Replace Clindamycin as the Adjunctive Antimicrobial of Choice in Group A Streptococcal Necrotizing Soft Tissue Infection and Toxic Shock Syndrome? A Focused Debate
  • Impact of Empiric Linezolid for Necrotizing Soft Tissue Infections on Duration of Methicillin-Resistant Staphylococcus aureus-Active Therapy

ANSWERED BY

Hunter O. Rondeau, Pharm.D. & Timothy P. Gauthier, Pharm.D., BCPS, BCIDP – May 2023


Q&A DISCLAIMER

The ID PharmD Q&A pages attempt to answer common pharmacy questions by providing the perspective and opinion of a trained expert with substantial knowledge relevant to the question. That noted, these answers are not provided as all-inclusive comprehensive responses.


For more…


 

LEARN ANTIBIOTICS

Paperback Book

Let’s Talk Micro

STEWARD PINS

Subscribe

Sign up for the monthly newsletter!

We will never spam you. We want you to like us. By clicking the Subscribe button, you accept the Terms of Service and Privacy Policy.

Categories

  • COVID-19
  • Healthcare At Large
  • Infectious Diseases & Antimicrobial Stewardship
  • Pharmacy News
  • Reality Check
  • Residency & Training
  • Facebook
  • Instagram
  • LinkedIn
  • Pinterest
  • Tumblr
  • Twitter
  • YouTube

Recent Posts

  • Five Inconvenient Truths To Know About Infectious Diseases
  • Reality Versus Expectation: TikTok As An Educational Tool For Teaching Bugs & Drugs
  • Pharmacy Student Study Strategies To Maximizing Learning In 2025 And Beyond
  • 5 Things To Know About Interpreting MRSA Nares Swab Results
  • Five Tidbits From The Largest International Meeting Of Clinical Microbiologists & Infectious Diseases Specialists In 2025

More Articles

5 Quick Tips For Pharmacy Residents Preparing Manuscripts

5 Quick Tips For Pharmacy Residents Preparing Manuscripts

5 Quick Things To Know About Drug Shortages

5 Quick Things To Know About Drug Shortages

Something Cool & Something Lame With 5 Antibiotics

Something Cool & Something Lame With 5 Antibiotics

5 Neat Things From The World Of Antimicrobials

5 Neat Things From The World Of Antimicrobials

Tags

antibiotic Antibiotics antimicrobial stewardship bcps beta-lactam cancer Chemotherapy Clinical Controversies clinical pharmacist clinical pharmacy community pharmacist Critical Care emergency medicine Emoji Game fellowship figure1 Hepatitis C hospital pharmacist hospital pharmacy Infectious Disease infectious diseases Lifestyle MRSA NAPLEX Natural Disaster oncology pharmacist one-on-one penicillin allergy PGY2 pharmacy fellowship Pharmacy Job pharmacy practice pharmacy residency pharmacy school pharmacy student Pharmacy technician PK-PD Compass Predatory Journals Rapid Diagnostic Testing residency social media student pharmacist study table transplant Zika

Recent

  • Five Inconvenient Truths To Know About Infectious Diseases
  • Reality Versus Expectation: TikTok As An Educational Tool For Teaching Bugs & Drugs
  • Pharmacy Student Study Strategies To Maximizing Learning In 2025 And Beyond
  • 5 Things To Know About Interpreting MRSA Nares Swab Results
  • Five Tidbits From The Largest International Meeting Of Clinical Microbiologists & Infectious Diseases Specialists In 2025

Search

Copyright 2016-2020 By Charlie Rose, LLC © · IDStewardship.com · Copyright · Privacy Policy · Terms · Contact